Oncotalks hematology videos and news

EHA

Interviews recorded at the European Hematology Association congress

EHA Prof. James Bussel, MD - TAPERING AND DISCONTINUATION OF THROMBOPOIETIN RECEPTOR AGONISTS IN ITP: EXPERT CONSENSUS OPINIONS

EHA Prof. James Bussel, MD - TAPERING AND DISCONTINUATION OF THROMBOPOIETIN RECEPTOR AGONISTS IN ITP: EXPERT CONSENSUS OPINIONS

Prof. James Bussel from the Well Cornel Medicine, New York, USA is commenting on the abstract MD TAPERING AND DISCONTINUATION OF THROMBOPOIETIN RECEPTOR AGONISTS IN ITP: EXPERT CONSENSUS OPINIONS which was presented at EHA 2019 in AmsterdamReference: EHA Library. Cooper N. Jun 14, 2019; 266508Link: https://library.ehaweb.org/eha/2019/24th/266508/nichola.cooper.tapering.and.discontinuation.of.thrombopoietin.receptor.html?f=listing%3D0%2Abrowseby%3D8%2Asortby%3D1%2Asearch%3D+TAPERING+AND+DISCONTINUATION+OF+THROMBOPOIETIN+RECEPTOR+AGONISTS+IN+ITP%3A+EXPERT+CONSENSUS+OPINIONS
EHA , Lithuania , Albania
00:07:29
EHA 2019 Jorge Cortes, MD, PhD

EHA 2019 Jorge Cortes, MD, PhD

Jorge Cortes, MD, PhD from the MD Anderson Cancer Center, Houston, USA is commenting on the abstract COMBINATION THERAPY USING ASCIMINIB PLUS IMATINIB (IMA) IN PATIENTS (PTS) WITH CHRONIC MYELOID LEUKEMIA (CML): RESULTS FROM A PHASE 1 STUDY presented at the EHA 2019 in AmsterdamReference: EHA Library. Kew S. Jun 15, 2019; 267466Link to abstract: https://library.ehaweb.org/eha/2019/24th/267466/sam.kew.combination.therapy.using.asciminib.plus.imatinib.28ima29.in.patients.html?f=listing%3D0%2Abrowseby%3D8%2Asortby%3D1%2Asearch%3DCOMBINATION+THERAPY+USING+ASCIMINIB+PLUS+IMATINIB+%28IMA%29+IN+PATIENTS+%28PTS%29+WITH+CHRONIC+MYELOID+LEUKEMIA+%28CML%29%3A+RESULTS+FROM+A+PHASE+1+STUDY
EHA , Lithuania , Albania
00:07:00
EHA 2019 Natalia Curto-Garcia, MD, PhD

EHA 2019 Natalia Curto-Garcia, MD, PhD

Natalia Curto-Garcia, MD, PhD from the Guys and St Thomas NHS Foundation Trust, London, United Kingdom is commenting on MOLECULAR ANALYSIS IN MAJIC PV CORRELATION WITH CLINICAL ENDPOINTS, which she presented at EHA 2019 in AmsterdamReference: EHA Library. Curto-Garcia N. Jun 16, 2019; 26736Link to abstract: https://library.ehaweb.org/eha/2019/24th/267361/natalia.curto-garcia.molecular.analysis.in.majic.pv.correlation.with.clinical.html?f=listing%3D0%2Abrowseby%3D8%2Asortby%3D1%2Asearch%3Dmolecular+analysis%2Bmajic+pv+correlation%2Bclinical+endpoints
EHA , Lithuania , Albania
00:02:21
EHA 2019 Prof. Michael Pfeilstöcker, MD

EHA 2019 Prof. Michael Pfeilstöcker, MD

Prof. Michael Pfeilstöcker, MD from the Heinrich-Heine University Hospital, Düsseldorf, Germany is commenting on 2 publications LONG-TERM OVERUSE OF CORTICOSTEROIDS IN THE REAL-WORLD TREATMENT OF PATIENTS WITH IMMUNE THROMBOCYTOPENIA IN THE US EXPLORYS AND MARKETSCAN DATABASES Reference: EHA Library. Bussel J. Jun 14, 2019; 266509Link to abstract: https://library.ehaweb.org/eha/2019/24th/266509/j.bussel.long-term.overuse.of.corticosteroids.in.the.real-world.treatment.of.html?f=listing%3D0%2Abrowseby%3D8%2Asortby%3D1%2Asearch%3DLONG-TERM+OVERUSE+OF+CORTICOSTEROIDS+IN+THE+REAL-WORLD+TREATMENT+OF+PATIENTS+WITH+IMMUNE+THROMBOCYTOPENIA+IN+THE+US+EXPLORYS+AND+MARKETSCAN+DATABASESDIFFERENCES IN PERCEPTIONS ON TREATMENT APPROACHES BETWEEN PHYSICIANS AND ITP PATIENTS: RESULTS FROM THE ITP WORLD IMPACT SURVEY (I-WISH) both presented at EHA 2019 in AmsterdamReference: EHA Library. Kruse A. Jun 14, 2019; 266510Link to abstract: https://library.ehaweb.org/eha/2019/24th/266510/alexandra.kruse.differences.in.perceptions.on.treatment.approaches.between.html?f=listing%3D0%2Abrowseby%3D8%2Asortby%3D1%2Asearch%3Dresults%2Bitp+world+impact+survey+%28i-wish
EHA , Latvia , Lithuania , Estonia , Albania
00:05:30
EHA 2019 Maria Dimou, MD, PhD

EHA 2019 Maria Dimou, MD, PhD

Maria Dimou, MD, PhD from the University of Athens, Athens, Greece is commenting on the abstract INITIAL REPORT OF A NILOTINIB DISCONTINUATION PROJECT WITH 54 GREEK CML PATIENTS FOLLOWED IN ACCORDANCE TO THE APPROVED DISCONTINUATION INDICATION OF THE DRUG which she presented at EHA 2019 in AmsterdamReference: EHA Library. Dimou M. Jun 15, 2019; 266809Link to abstract: https://library.ehaweb.org/eha/2019/24th/266809/maria.dimou.initial.report.of.a.nilotinib.discontinuation.project.with.54.html?f=listing%3D0%2Abrowseby%3D8%2Asortby%3D1%2Asearch%3DINITIAL+REPORT+OF+A+NILOTINIB+DISCONTINUATION+PROJECT+WITH+54+GREEK+CML+PATIENTS+FOLLOWED+IN+ACCORDANCE+TO+THE+APPROVED+DISCONTINUATION+INDICATION+OF+THE+DRUG
EHA , Lithuania
00:06:18
EHA 2019 Jeroen Janssen, MD, PhD

EHA 2019 Jeroen Janssen, MD, PhD

Jeroen Janssen MD, PhD from the Amsterdam UMC, Amsterdam, The Netherlands is commenting on the abstract COMBINATION THERAPY USING ASCIMINIB PLUS IMATINIB (IMA) IN PATIENTS (PTS) WITH CHRONIC MYELOID LEUKEMIA (CML) & COMBINATION OF ASCIMINIB PLUS NILOTINIB (NIL) OR DASATINIB (DAS) IN PATIENTS (PTS) WITH CHRONIC MYELOID LEUKEMIA Reference: EHA Library. Kew S. Jun 15, 2019; 267467Link to abstract: https://library.ehaweb.org/eha/2019/24th/267467/sam.kew.combination.of.asciminib.plus.nilotinib.28nil29.or.dasatinib.28das29.in.html?f=listing%3D0%2Abrowseby%3D8%2Asortby%3D1%2Asearch%3Dasciminib
EHA , Latvia , Lithuania , Estonia , Albania
00:05:04
EHA 2019 Stephan Grupp, MD, PhD

EHA 2019 Stephan Grupp, MD, PhD

Stephan Grupp, MD, PhD from the Children’s Hospital of Philadelphia, Philadelphia, USA is commenting on the abstract: TISAGENLECLEUCEL APPEARS EFFECTIVE AND SAFE IN PEDIATRIC AND YOUNG ADULT PATIENTS WITH RELAPSED/REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA WITH HIGH-RISK CYTOGENETIC ABNORMALITIES which he presented at EHA 2019 in AmsterdamReference: EHA Library. A. Grupp S. Jun 16, 2019; 267372link to abstract: https://library.ehaweb.org/eha/2019/24th/267372/stephan.a.grupp.tisagenlecleucel.appears.effective.and.safe.in.pediatric.and.html?f=listing%3D0%2Abrowseby%3D8%2Asortby%3D1%2Asearch%3Dtisagenlecleucel+appears+effective%2Bsafe%2Bpediatric%2Byoung+adult+patients%2Brelapsed%2Frefractory+acute+lymphoblastic+leukemia%2Bhigh-risk+cytogenetic+abnormalities%E2%80%8B
EHA , Lithuania , Albania
00:06:51
  • «
  • 1
  • 2

This website intends to use cookies to improve the site and your experience. By continuing to browse the site you are agreeing to accept our use of cookies . If you require further information and/or do not wish to have cookies placed when using the site, visit Privacy Notice.

On acceptance: use all cookie settings
On denial: use only necessary cookies